Pediatric Advisory Committee Will Preview CDK & PD-1 Inhibitors
This article was originally published in The Pink Sheet Daily
Pediatric subcommittee of the Oncologic Drugs Advisory Committee will discuss pediatric development plans for Novartis’ CDK inhibitor LEE011 and two immune checkpoint inhibitors, Bristol’s nivolumab and Merck’s MK-3475.
You may also be interested in...
As FDA looks toward more flexible cancer drug development standards, advisory panel indicates Novartis’ proposed pediatric indications for CDK inhibitor could be candidate for single-arm studies.
The combination of two novel drugs from Cyclacel inflicts a form of synthetic lethality in which sapacitabine causes DNA defects, rendering tumor cells vulnerable to seliciclib, which thwarts the repair process and is lethal in its own right, the lead investigator reported April 7 at the American Association for Cancer Research meeting in Washington, D.C.
Pfizer’s novel oral CDK 4/6 inhibitor PD-03392991, in combination with letrozole, delivered a statistically and clinically significant increase in median progression-free survival for women with advanced ER+/HER2- breast cancer, according to interim Phase II data presented Dec. 5 at the San Antonio Breast Cancer Symposium.